In fact, breast cancer cells, treated with APRIL or BAFF, display a more aggressive phenotype, as they exhibit: (1) increased migration and parallel modifications of the actin cytoskeleton; (2) increased expression of mesenchymal markers and signs of the acquisition of a mesenchymal phenotype. This evidence concerns the gene TNFSF13 and breast carcinoma.